AU2002317604A1 - Immunologically significant herpes simplex virus antigens and methods for using same - Google Patents

Immunologically significant herpes simplex virus antigens and methods for using same

Info

Publication number
AU2002317604A1
AU2002317604A1 AU2002317604A AU2002317604A AU2002317604A1 AU 2002317604 A1 AU2002317604 A1 AU 2002317604A1 AU 2002317604 A AU2002317604 A AU 2002317604A AU 2002317604 A AU2002317604 A AU 2002317604A AU 2002317604 A1 AU2002317604 A1 AU 2002317604A1
Authority
AU
Australia
Prior art keywords
hsv
herpes simplex
simplex virus
amino acids
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002317604A
Other languages
English (en)
Inventor
Hongbo Chen
Nancy Ann Hosken
David M. Koelle
Patrick Mcgowan
Christine M. Posavad
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Corixa Corp
Fred Hutchinson Cancer Center
Original Assignee
University of Washington
Corixa Corp
Fred Hutchinson Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington, Corixa Corp, Fred Hutchinson Cancer Center filed Critical University of Washington
Publication of AU2002317604A1 publication Critical patent/AU2002317604A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2002317604A 2001-07-31 2002-07-31 Immunologically significant herpes simplex virus antigens and methods for using same Abandoned AU2002317604A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US30892301P 2001-07-31 2001-07-31
US60/308,923 2001-07-31
US30942801P 2001-08-01 2001-08-01
US60/309,428 2001-08-01
PCT/US2002/024306 WO2003011893A2 (en) 2001-07-31 2002-07-31 Immunologically significant herpes simplex virus antigens and methods for using same

Publications (1)

Publication Number Publication Date
AU2002317604A1 true AU2002317604A1 (en) 2003-02-17

Family

ID=26976523

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002317604A Abandoned AU2002317604A1 (en) 2001-07-31 2002-07-31 Immunologically significant herpes simplex virus antigens and methods for using same

Country Status (8)

Country Link
US (2) US6814969B2 (enExample)
EP (2) EP2191845A1 (enExample)
JP (1) JP4519461B2 (enExample)
AT (1) ATE488249T1 (enExample)
AU (1) AU2002317604A1 (enExample)
CA (1) CA2454750C (enExample)
DE (1) DE60238330D1 (enExample)
WO (1) WO2003011893A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004009021A2 (en) 2002-07-18 2004-01-29 University Of Washington Rapid, efficient purification of hsv-specific t-lymphocytes and hsv antigens identified via same
US8541002B2 (en) 2003-09-12 2013-09-24 Agenus Inc. Vaccine for treatment and prevention of herpes simplex virus infection
JP5118018B2 (ja) 2005-04-15 2013-01-16 ヒューマン マトリックス サイエンシーズ、エルエルシー 植物由来のエラスチン結合タンパク質リガンドおよびその使用方法
CA2523032A1 (en) * 2005-10-07 2007-04-07 Immunovaccine Technologies Inc. Vaccines for cancer therapy
AU2007275047A1 (en) 2006-07-20 2008-01-24 University Of Washington Compositions and methods for vaccinating against HSV-2
US20100055132A1 (en) * 2007-04-04 2010-03-04 Thomas Dag Horn Non-specific delayed-type hypersensitivity response to treat herpes simplex virus infection
EP2197497B1 (en) 2007-09-27 2016-06-01 ImmunoVaccine Technologies Inc. Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo
US20100209452A1 (en) * 2007-10-03 2010-08-19 Immunovaccine Technologies, Inc Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
JP5715051B2 (ja) * 2008-06-05 2015-05-07 イムノバクシーン・テクノロジーズ・インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． リポソーム、抗原、ポリヌクレオチド及び疎水性物質の連続相を含む担体を含む組成物
US8460674B2 (en) * 2009-02-07 2013-06-11 University Of Washington HSV-1 epitopes and methods for using same
US9044447B2 (en) 2009-04-03 2015-06-02 University Of Washington Antigenic peptide of HSV-2 and methods for using same
ES2732815T3 (es) 2009-05-22 2019-11-26 Genocea Biosciences Inc Vacunas frente al virus del herpes simple de tipo 2: composiciones y métodos para provocar una respuesta inmunitaria
US20130224236A1 (en) * 2010-11-03 2013-08-29 University Of Washington Hsv-1 epitopes and methods for using same
CA2856697A1 (en) 2010-11-24 2012-06-07 Genocea Biosciences, Inc. Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
US10105435B2 (en) 2011-10-06 2018-10-23 Immunovaccine Technologies Inc. Liposome compositions comprising an adjuvant that activates or increases the activity of TLR2 and uses thereof
AU2012340712B2 (en) 2011-11-23 2017-09-14 Genocea Biosciences, Inc. Nucleic acid vaccines against Herpes Simplex Virus type 2: compositions and methods for eliciting an immune response
SMT201800368T1 (it) 2012-05-16 2018-09-13 Immune Design Corp Vaccini per l'infezione da virus-2 herpes simplex
CN107427540A (zh) 2015-02-26 2017-12-01 斯垮瑞斯有限责任公司 用于治疗单纯疱疹病毒感染的非特异性延迟型过敏反应
CA3017555A1 (en) * 2016-03-14 2017-09-21 Redbiotec Ag Means and methods for treating hsv
JP2019537555A (ja) 2016-09-28 2019-12-26 ジェノセア バイオサイエンシーズ， インコーポレイテッド ヘルペスを処置するための方法および組成物
US20200164060A1 (en) * 2017-07-21 2020-05-28 Fred Hutchinson Cancer Research Center Herpes simplex virus vaccine epitopes specifically recognized by tissue resident memory t cells
CN112710849A (zh) * 2020-12-24 2021-04-27 首都医科大学附属北京友谊医院 一种鉴定抗EBV免疫活性的ELISpot试剂盒、制备方法及应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4859587A (en) 1984-06-04 1989-08-22 Institut Merieux Recombinant herpes simplex viruses, vaccines and methods
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
EP0541692B1 (en) 1990-08-02 1999-05-06 Chiron Corporation Herpes simplex virus vp16 vaccines
CA2090295A1 (en) 1992-02-03 1993-08-04 Anthony B. Nesburn Process for the expression of herpes simplex virus type 1 glycoprotein e and methods of use
US5426039A (en) 1993-09-08 1995-06-20 Bio-Rad Laboratories, Inc. Direct molecular cloning of primer extended DNA containing an alkane diol
ATE365808T1 (de) 1995-07-28 2007-07-15 Marie Curie Cancer Care Transportproteine und deren verwendungen
GB9615726D0 (en) * 1996-07-26 1996-09-04 Medical Res Council Anti-viral agent 11
EP0948508A4 (en) 1996-11-04 2001-11-07 Smithkline Beecham Corp NEW CODING SEQUENCES FOR HERPES SIMPLEX TYPE 2 VIRUS
US6017735A (en) * 1997-01-23 2000-01-25 Marie Curie Cancer Care Materials and methods for intracellular transport and their uses
EP0984790A1 (en) * 1997-06-02 2000-03-15 Chiron Corporation Herpes simplex virus vp22 vaccines and methods of use
TR200100373T2 (tr) * 1998-08-07 2001-09-21 University Of Washington İmünolojik uçuk virüsü antijenleri ve bunların kullanım yöntemleri
NZ531980A (en) * 1999-09-30 2005-04-29 Univ Washington Pharmaceutical compositions comprising epitopes of the UL47 gene or protein ( encodes VP13/14 ) for the treatment and prevention of herpes simplex virus ( HSV ) and methods of producing immune cells
NZ522734A (en) * 2000-06-29 2005-05-27 Corixa Corp Compositions and methods for the diagnosis and treatment of herpes simplex virus infection using immunogneic portions of an HSV antigen
US6821519B2 (en) * 2000-06-29 2004-11-23 Corixa Corporation Compositions and methods for the diagnosis and treatment of herpes simplex virus infection

Also Published As

Publication number Publication date
US20030190324A1 (en) 2003-10-09
US6814969B2 (en) 2004-11-09
EP1420821B8 (en) 2011-02-02
US7037509B2 (en) 2006-05-02
EP2191845A1 (en) 2010-06-02
WO2003011893A2 (en) 2003-02-13
EP1420821A2 (en) 2004-05-26
EP1420821A4 (en) 2006-08-30
JP2004537308A (ja) 2004-12-16
EP1420821B1 (en) 2010-11-17
JP4519461B2 (ja) 2010-08-04
US20040241182A1 (en) 2004-12-02
CA2454750A1 (en) 2003-02-13
ATE488249T1 (de) 2010-12-15
CA2454750C (en) 2012-09-18
WO2003011893A3 (en) 2003-09-12
DE60238330D1 (de) 2010-12-30

Similar Documents

Publication Publication Date Title
EP1420821B8 (en) Immunologically significant herpes simplex virus antigens and methods for using same
EP2011510A3 (en) Pharmaceutical compositions comprising immunologically active herpes simplex virus (HSV) protein fragments
NZ551802A (en) A hyperimmune serum-reactive antigen consisting of a polypeptide comprising an amino acid sequence in SEQ ID NO:422 and antigenic fragments thereof
EP1175909A8 (en) Therapeutic methods and compositions based on serrate proteins and nucleic acids
US4769239A (en) Vaccine against varicella-zoster virus
CA2202652A1 (en) Production of peptides in plants as viral coat protein fusions
CA2032153A1 (fr) Application de nouveaux fragments d'adn en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
AU6435394A (en) Fusion proteins between antigenic amino acid sequences and beta-2-microglobulin
AU5243593A (en) Synthetic peptides, antibodies against them and their use
IL135687A0 (en) A novel human checkpoint kinase, hcds1, compositions and methods
AU2002307510A1 (en) Cytokine protein family
CA2303478A1 (en) Group a streptococcal vaccines
CA2115579A1 (en) Ryegrass pollen allergen
PT1417222E (pt) Polipéptidos isolados baseados no epítopo neutralizante da proteína p17 de vih, úteis como vacinas, e anticorpos antip17 neutralizantes que reconhecem especificamente o referido polipéptido neutralizante
MX2022014649A (es) Coctel de peptidos.
CA2096532A1 (en) New human recombinant gamma-interferon
PT635025E (pt) Processo para preparar proteinas modificadas
WO1997003198A3 (en) Nucleotide and amino acid sequence and uses thereof
AU1444699A (en) Single-chain polypeptides comprising troponin i and troponin
GB9820002D0 (en) Novel compounds
AU7655994A (en) Cloning of a member of the serine-threonine-kinase family
GB2234246B (en) Polypeptide inhibitor of viral replication
GB2357507A (en) Peptide fragments of cholera toxin B or enterotoxin B as vaccine adjuvants
WO2001070774B1 (en) Human t cell response to mhc-binding motif clusters
WO2000034294A3 (en) Tumor necrosis factor receptor homologue-1 ('trh1')

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase